Abstract 4137045: Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential

Livia Stanger(University of Michigan), Michael Holinstat(Thomas Jefferson University), Björn Dahlöf(Sahlgrenska University Hospital), Pooja Yalavarthi(University of Michigan), Mariane Flores(University of Michigan)

Circulation

November 12, 2024

10.1161/circ.150.suppl_1.4137045

Cited by 0

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

|The Lancet|2010|518

An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis

|Cell|2024|102